Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evobrutinib (Primary) ; Dimethyl fumarate
Indications Multiple sclerosis
Focus Proof of concept; Therapeutic Use
Sponsors EMD Serono; EMD Serono Research & Development Institute; Merck KGaA

30 May 2024 This trial has been completed in Czech republic and Bulgaria, according to European Clinical Trials Database record.
22 Apr 2024 Status changed from active, no longer recruiting to discontinued.
01 Apr 2024 Results of the Phase II open-label extension (OLE; up to week 192 from randomisation) and a cerebrospinal fluid (CSF) sub-study, published in the Multiple Sclerosis Journal

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com